GlaxoSmithKline's ($GSK) Horizant (gabapentin enacarbil), a treatment for restless leg syndrome, has landed on the FDA shortage list and the company is pointing to problems with a contract manufacturer as the cause, according to Outsourcing-Pharma. The problem has come up even as GSK is in the midst of turning the product over to its partner; XenoPort takes ownership May 1, but GSK has agreed to handle manufacturing through October. The company said it expects the "spot shortage" to persist into June. Story | More